source
- Eli Lilly acquires Calytrix Bio in $1.5 billion deal to add myelofibrosis antibody to its pipelineEli Lilly announced a $1.5 billion acquisition of Massachusetts‑based Calytrix Bio, gaining access to the company’s biparatopic antibody aimed at mutant calreticulin‑driven essential thrombocythemi…
- Wave Life Sciences reports stronger weight-loss effect of WVE-007 in patients with higher BMI and excess body fatWave Life Sciences presented data at ObesityWeek 2026 from its mid-stage INLIGHT trial of the investigational siRNA drug WVE-007. The analysis of three cohorts showed that participants with higher…BioSpace · 1h agoPositive readoutPositive